1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Overall characteristics of the study population
Characteristics
Patient characteristics 
 Age (mean) (range) 64.6 ± 12.6 (29–86)
 Male sex (No./No.) (%) 69/95 (72.6%)
 Left-hemisphere stroke (No./No.) (%) 56/95 (58.9%)
 Baseline NIHSS (mean) (range) 16.8 ± 5.5; 2–32
 Baseline ASPECTS (median) (range) 8; 2–10
 Tobacco (No./No.) (%) 35/95 (36.8%)
 Diabetes mellitus (No./No.) (%) 7/95 (7.4%)
 Dyslipidemia (No./No.) (%) 16/95 (16.8%)
 Atrial fibrillation at admission (No./No.) (%) 10/95 (10.5%)
 Prestroke antiplatelet therapy (No./No.) (%) 21/95 (22.1%)
Procedural and postprocedural characteristics 
 Onset-to-groin time (mean) (range) 284.5 ± 156.4; 70–980 min
 Onset-to-recanalization (mean) (range) 376.7 ± 168.3; 110–1075 min
 Procedural time (mean) (range) 90.6 ± 58.2; 9–315 min
 No. of MT attempts (mean) (range) 2.57 ± 1.7; 1–10
 Successful recanalization mTICI ≥2b (No./No.) (%) 58/95 (61.1%)
 Intravenous thrombolysis (No./No.) (%) 45/95 (47.4%)
 Single-layer carotid stent (No./No.) (%) 87/95 (91.6%)
 Dual-layer carotid stent (No./No.) (%) 8/95 (8.4%)
 Intraprocedural heparin (No./No.) (%) 40/95 (42.1%)
 Intraprocedural single-antiplatelet therapy (No./No.) (%) 46/79 (58.2%)
 Intraprocedural dual-antiplatelet therapy (No./No.) (%) 10/43 (23.3%)
 Postprocedural single-antiplatelet therapy (No./No.) (%) 25/54 (46.3%)
 Postprocedural dual-antiplatelet therapy (No./No.) (%) 30/60 (50%)
 Symptomatic ICH 26/94 (27.7%)
Note:—mTICI indicates modified TICI.